Mind Medicine Inc Ordinary Shares MNMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MNMD is a good fit for your portfolio.
News
-
MindMed to Present at Upcoming May Medical Conferences
-
MindMed to Present at Upcoming April Medical Conferences
-
MindMed Announces Voluntary Delisting from Cboe Canada
-
Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?
-
Thinking about buying stock in Ocugen, Akebia Therapeutics, Mind Medicine, SoundHound AI, or Canopy Growth?
-
Thinking about buying stock in Entera Bio, Ocugen, Mind Medicine, MicroAlgo, or Flora Growth?
-
Thinking about buying stock in MicroCloud Hologram, Akebia Therapeutics, Mind Medicine, Treasure Global, or Getty Images?
-
Thinking about buying stock in Mind Medicine, Ocean Biomedical, Archer Aviation, Outlook Therapeutics, or Cardiff Oncology?
Trading Information
- Previous Close Price
- $8.52
- Day Range
- $8.36–8.76
- 52-Week Range
- $2.41–12.22
- Bid/Ask
- $8.35 / $8.50
- Market Cap
- $600.67 Mil
- Volume/Avg
- 652,548 / 2.4 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.mindmed.co
Comparables
Valuation
|
Metric
|
MNMD
|
CRNX
|
BLU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.48 | 5.33 | 5.83 |
Price/Sales | — | 609.51 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MNMD
CRNX
BLU
Financial Strength
|
Metric
|
MNMD
|
CRNX
|
BLU
|
|---|---|---|---|
Quick Ratio | 3.09 | 12.92 | 32.13 |
Current Ratio | 3.22 | 13.07 | 33.42 |
Interest Coverage | — | — | −1,125.80 |
Quick Ratio
MNMD
CRNX
BLU
Profitability
|
Metric
|
MNMD
|
CRNX
|
BLU
|
|---|---|---|---|
Return on Assets (Normalized) | −45.88% | −38.81% | −21.75% |
Return on Equity (Normalized) | −59.97% | −44.79% | −26.24% |
Return on Invested Capital (Normalized) | −61.04% | −45.62% | −24.47% |
Return on Assets
MNMD
CRNX
BLU
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vckxbxjn | Yctzx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pvhhpqvt | Rgbdyn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Njbfpwt | Nnwvlb | $97.8 Bil | |
MRNA
| Moderna Inc | Qqmrtkw | Xsntc | $41.3 Bil | |
ARGX
| argenx SE ADR | Slsrzjsy | Tffd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Myjwbmskm | Zls | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qhbjbjktv | Kxkhkfq | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ggxbwpfm | Clrckb | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mwbblykcr | Xtjxh | $12.5 Bil | |
INCY
| Incyte Corp | Ycnhxby | Fzpfqt | $11.6 Bil |